Type 3 Gaucher DiseaseNCT07675031
Managed Access Program of Venglustat in Pediatric and Adult Patients With Type 3 Gaucher Disease (GD3).
A study testing GZ402671 in people with Type 3 Gaucher Disease, run by Sanofi.
Trial summary
The objective of this program is to provide early access to venglustat for certain patients with Gaucher disease type 3 in response to unsolicited requests from healthcare providers. No approved therapies for the CNS manifestations of the disease are currently available. Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Type 3 Gaucher Disease
- What is being tested?
- GZ402671
- Type of treatment
- Pill or oral medicine
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- Child, Adult, Older adult
Who may be able to join
- ≥ 12 years of age
- Clinical diagnosis of GD3 with at least 1 CNS manifestation
- Body weight ≥15 kg
- On a stable ERT dose for at least 6 months
- Clinically stable with respect to hematologic manifestations
- Clinically stable with respect to spleen and liver volume
Show all 9Show fewer
- If the patient has a history of seizures, they must be well controlled without use of medications that are strong/moderate inducers or strong/moderate inhibitors of CYP3A
- Documented negative pregnancy test
- Contraceptive use consistent with local regulations.
Who cannot join
- Inability to safely swallow (or chew and swallow) a venglustat tablet
- Use of any investigational drugs within the last 30 days or 5 half-lives or gene therapy at any time
- Current use of any unapproved therapy for GD
- Pregnant or breastfeeding females
- Drug contraindications
- History of major organ transplant (eg, bone marrow or liver)
Show all 10Show fewer
- History of drug and/or alcohol abuse within the last year
- Patients with severe depression and/or a history of a major affective disorder in the past year
- Patients with suicidal ideation or behavior prior to study.
- The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Trial locations and contacts
No sites are listed yet.
Trial Transparency email recommended (Toll free for US & Canada) contact
About this study
The objective of this program is to provide early access to venglustat for certain patients with Gaucher disease type 3 in response to unsolicited requests from healthcare providers. No approved therapies for the CNS manifestations of the disease are currently available. The program will provide access to venglustat prior to registration and the availability of commercial product (including reimbursement where applicable) in the country of the patient.
Read the detailed description
The program provides access to venglustat, an investigational therapy.
- Conditions
- Type 3 Gaucher Disease
- Being tested
- GZ402671
- Medical subject headings
- Gaucher Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GZ402671Drug
Patients will receive venglustat tablets orally.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 3 Gaucher DiseaseStudies of the same condition, open and under way.
- More trials run by SanofiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- Sanofi
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07675031
- Sponsor's protocol ID
- SCP25092
- Status last verified
- Jun 2026
- First submitted
- 7 Apr 2026
- Last updated
- 30 Jun 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Managed Access Program of Venglustat in Pediatric and Adult Patients With Type 3 Gaucher Disease (GD3).
- ClinicalTrials.gov ID
- NCT07675031
- Acronym / sponsor ID
- SCP25092
- Conditions
- Type 3 Gaucher Disease
- Study type
- Expanded access
- Recruitment status
- Available
- Lead sponsor
- SanofiIndustry (pharma, biotech, devices)
- First posted
- 30 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this program is to provide early access to venglustat for certain patients with Gaucher disease type 3 in response to unsolicited requests from healthcare providers. No approved therapies for the CNS manifestations of the disease are currently available. The program will provide access to venglustat prior to registration and the availability of commercial product (including reimbursement where applicable) in the country of the patient.
Detailed description
The program provides access to venglustat, an investigational therapy.
Study design
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (9 listed)
- ≥ 12 years of age
- Clinical diagnosis of GD3 with at least 1 CNS manifestation
- Body weight ≥15 kg
- On a stable ERT dose for at least 6 months
- Clinically stable with respect to hematologic manifestations
Key exclusion criteria (10 listed)
- Inability to safely swallow (or chew and swallow) a venglustat tablet
- Use of any investigational drugs within the last 30 days or 5 half-lives or gene therapy at any time
- Current use of any unapproved therapy for GD
- Pregnant or breastfeeding females
- Drug contraindications
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GZ402671Patients will receive venglustat tablets orally. | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2026.
Related trials for Type 3 Gaucher Disease
Not yet recruitingPhase 2/3
Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
Niemann-Pick Disease Type C, GM2 Gangliosidosis
RecruitingPhase 3
A Gaucher Disease Gene Therapy Trial With FLT201
Gaucher Disease Type 1
Not yet recruitingPhase 3
Study of Velaglucerase Beta ERT in Children With Gaucher Disease
Gaucher Disease, Gaucher Disease Type 1
RecruitingObservational study
MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)
Gaucher Disease, Type 3
Not yet recruitingPhase 2
Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)
Gaucher Disease Type 3
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Trial Transparency email recommended (Toll free for US & Canada) contact
Questions about this trial
What is this clinical trial studying?
A study testing GZ402671 in people with Type 3 Gaucher Disease, run by Sanofi.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Trial Transparency email recommended (Toll free for US & Canada) (800-633-1610 ext. option 6, Contact-US@sanofi.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026.